Novel Oral Anticoagulants for Atrial Fibrillation: Time for a New Paradigm
Stavros Stavrakis, MD, Assistant Professor, Department of Medicine/Cardiovascular Diseases
Disclosure Report: Course Director:
Upon completion of this activity, participants will be able to: To review the stratification of stroke and bleeding risk in patients with atrial fibrillation. To review the pharmacology and efficacy of the new oral anticoagulants. To describe a new paradigm for anticoagulation in patients with atrial fibrillation.
Dr. Michael Bronze has no financial relationships or affiliations to disclose. Planning Committee Members: Dr. Ben Cowley has been a consultant for Otsuka. He has received honorarium from NKF. Dr. Courtney Houchen has received other financial or material support in that he is the Founder of COARE Biotechnology. Dr. James Lane has received grants/research support from Novo Nordisk, VM BioPharma, Boehringer-Ingelheim, PhaseBio Pharmaceuticals, Inc., EMD Serono, Inc, Merck Sharp & Dohme Corp, Eli Lilly and Company, Andromeda Biotech Ltd, Concept Therapeutics, Inc., Tranzyme, Inc, and Sanofi-Aventis. Dr. Dwight Reynolds has received grants/research support from Medtronic. He has been a consultant for Medtronic. He has received honorarium from Medtronic. Drs. Jackson, Kinasewitz, Selby, Drevets, Humphrey and Zou have no financial relationships or affiliations to disclose. Course Contact: Ms. Brenda Wilkerson has no financial relationships or affiliations to disclose. Speaker:
Dr. Stavrakis has no financial relationships or affiliations to disclose.
Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability. Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.
For further information contact:
271-6651 ext. 54374